Sanofi
A global biopharmaceutical company that discovers, develops, and markets medicines and vaccines.
SAN | PA
Overview
Corporate Details
- ISIN(s):
- FR0000120578 (+39 more)
- LEI:
- 549300E9PC51EN656011
- Country:
- France
- Address:
- 46 AVENUE DE LA GRANDE ARMEE, 75017 PARIS
- Sector:
- Manufacturing
Description
Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-02-23 20:02 |
IRANNOTICE
|
English | 12.1 KB | ||
| 2024-02-23 18:45 |
Communiqué de presse : Dépôt du Document d’Enregistrement Universel 2023, conte…
|
French | 112.3 KB | ||
| 2024-02-23 18:45 |
Press Release: Filing of the 2023 U.S. Form 20-F and French “Document d’Enregis…
|
English | 116.5 KB | ||
| 2024-02-23 17:33 |
Document d'Enregistrement Universel
|
French | 18.1 MB | ||
| 2024-02-23 17:33 |
Document d'Enregistrement Universel
|
French | 18.1 MB | ||
| 2024-02-23 17:15 |
20-F
|
English | 32.7 MB | ||
| 2024-02-23 16:33 |
Annual Report 2023 Form 20F
|
English | 7.6 MB | ||
| 2024-02-23 16:33 |
Annual Report 2023 Form 20F
|
English | 7.6 MB | ||
| 2024-02-23 07:00 |
Press Release: Dupixent® sBLA accepted for FDA Priority Review for treatment of…
|
English | 197.3 KB | ||
| 2024-02-23 07:00 |
Communiqué de presse : La FDA accorde un examen prioritaire à la demande de lic…
|
French | 205.4 KB | ||
| 2024-02-22 19:02 |
Communiqué de presse : Le Conseil d’administration de Sanofi propose la nominat…
|
French | 149.8 KB | ||
| 2024-02-22 19:02 |
Press Release: Sanofi’s Board of Directors proposes the appointment of Clotilde…
|
English | 159.2 KB | ||
| 2024-02-20 23:40 |
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Janvi…
|
French | 121.7 KB | ||
| 2024-02-20 23:40 |
Sanofi: Information concerning the total number of voting rights and shares - J…
|
English | 145.3 KB | ||
| 2024-02-16 07:00 |
Press Release: Japan first in the world to approve Dupixent® for chronic sponta…
|
English | 182.2 KB |
Automate Your Workflow. Get a real-time feed of all Sanofi filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Sanofi
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Sanofi via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-05-02 | N/A | Other | Buy | 71,423 | N/A |
| 2024-04-26 | N/A | Other | Buy | 1,000 | 91,380.00 EUR |
| 2023-06-09 | N/A | Other | Buy | 9 | 856.04 EUR |
| 2023-05-02 | N/A | Other | Buy | 65,205 | 6,364,008.00 EUR |
| 2023-05-02 | N/A | Other | Buy | 500 | 48,835.00 EUR |
Peer Companies
